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a b s t r a c t
Aripiprazole is a dopamine D2- and serotonin 5-hydroxytryptamine (5-HT)1A receptor partial
agonist and 5-HT2A receptor antagonist primarily used for the treatment of schizophrenia,
bipolar disorder or depression with psychotic ideation. However, recently a number of new
possible indications have been suggested, among them Gilles de la Tourette syndrome (GTS).
In two randomized, double-blind, placebo-controlled studies in children and adolescents
with GTS has been conﬁrmed the efﬁcacy of aripiprazole in tic reduction. In comparison to
other neuroleptics, aripiprazole seems to be similarly effective. What is more, the number
and proﬁle of possible adverse effects is also favorable. As a consequence, aripiprazole had
been registered by Food and Drug Administration (FDA) for the treatment of tics and
represents new therapeutic option in treatment of GTS.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http://www.elsevier.com/locate/pjnns1. Introduction
Gilles de la Tourette syndrome (GTS) is a neuropsychiatric
disorder affecting children and adults. The number of children
aged 5–18 with GTS in Poland is estimated to be around 50 000.
The main symptoms of this disease are motor and vocal tics.
Tics are sudden, non-rhythmic, repetitive involuntary move-
ments or vocalizations. Tics are found in all GTS patients.
80–90% of individuals with GTS are diagnosed with psychiatric
comorbidities, the most frequent are: attention deﬁcit hyper-
activity disorder (ADHD), obsessive-compulsive disorder
(OCD), anxiety disorders, depression, autism spectrum dis-
orders, behavioral disorders and oppositional deﬁant disorder
(ODD). The exact cause of the disease is unknown, but genetic* Corresponding author.
E-mail addresses: piotr.janik@wum.edu.pl (P. Janik), natalia.szejko
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0028-3843/© 2017 Polish Neurological Society. Published by Elsevier Scauses seem to play the main role. Therefore, only symptom-
atic treatment is available. Nevertheless, the majority of
patients do not require any therapeutic intervention, because
symptoms are benign. Only if tics are affecting signiﬁcantly
everyday life and social functioning, behavioral or pharmaco-
logical treatment is introduced. The most commonly used
drugs are ﬁrst-generation antipsychotics (haloperidol, pimo-
zide, ﬂuphenazine) and second-generation antipsychotics
(aripiprazole, sulpiride, tiapride, risperidone, ziprasidone),
clonidine, topiramate, tetrabenazine. Behavioral interventions
based on the habit reversal technique (HRT) or exposure
prevention response therapy are treatment of choice, but
due to limited access they are not always available. Rescue
and still experimental therapy remains operation of deep brain
stimulation (DBS).@gmail.com (N. Szejko).
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Efﬁcacy of aripiprazole among children and adolescents with
GTS was conﬁrmed in two randomized, double-blind, placebo-
controlled studies published in 2013 and 2017 [1,2]. In both
studies drug efﬁcacy was proved by signiﬁcant tic reduction in
Yale Global Tic Severity Scale – Total Tic Score (YGTSS-TTS,
range: 0–50) and Clinical Global Impression Scale (CGI). TTS is
used to evaluate tic severity during the last week before clinical
examination and it contains the following parts: number,
frequency, intensity, complexity and interference with daily
activities (all items ranged 0–4; total range: 0–25 for motor and
vocal tics). CGI measures global improvement rated on a 7-point
scale. CGI scores from 1 (very much improved) through to 7 (very
much worse) and describe the change or improvement (if any) in
different aspects of global functioning. Sallee et al. investigated
the effect of aripiprazole among 133 patients aged 7–17 with at
least moderate tics affecting daily life (TTS ≥ 20). Patients were
randomized to three therapeutic groups: low-dose (<50 kg –
5 mg/day; >50 kg – 10 mg/day), high-dose (<50 kg – 10 mg/day;
>50 kg – 20 mg/day) and placebo. The study lasted for 8 weeks.
Both low and high drug doses were effective in tic reduction in
TTS, accordingly for 6.3 and 9.9 (after adjustment to placebo
effect), in comparison to placebo group. This change was
statistically signiﬁcant already in the ﬁrst week of treatment.
Tics were reduced in average by half (45.9% in low-dose group
and 54.2% in high-dose group). This effect was pronounced both
for motor and vocal tics and impact on daily functioning (YGTSS
Impairment of Global Functioning Scale). The vast majority of
patients improved much or very much (CGI, 69% from low-dose
group, 74.3% from high-dose group) that was also adequate to
TTS results surpassing 25% tic reduction. In approximately 50%
of cases improvement higher than 50% was reported (YGTSS-
TTS: 40.5% and 57.1% of patients). The use of aripiprazole leaded
to 5–6 higher dose-dependent chance of clinical improvement in
comparison to placebo therapy. NNT, number needed to treat, in
high-dose group was 3 and in low-dose group 5. In all study
endpoints the efﬁcacyofdrugwas dose-dependent and higher in
high-dose group compared to low-dose group [1].
The second randomized, double-blind, placebo-controlled,
multicenter study was conducted in South Korea and included
61 children and adolescents aged 6–18 with TTS ≥22 [2]. The
average tic reduction in TTS (combined motor and vocal tic
score) after 10 weeks of treatment was of 5.3, after adjustment
to placebo-effect (with average tic reduction by 52.9%
comparing to baseline TTS). Nevertheless, the reduction of
motor tic severity subscale was not statistically signiﬁcant.
Group treated with aripiprazole improved much or very much
in CGI as to placebo group (66% vs. 45%). Differently to study
from 2017, drug-dose was not previously established, but was
evaluated in relation to clinical response. The average dose of
aripiprazole used in this trial was of 11.0 mg/day [2].
3. Efﬁcacy of aripiprazole in comparison to
other therapeutic options
In both studies tics were reduced for more than 50%. This gives
even better clinical outcome than on treatment with otherwidely-used, symptomatic drugs (haloperidol, pimozide,
risperidone, ziprasidone, clonidine, guanfacine), which
efﬁcacy was evaluated in randomized, double-blind, place-
bo-controlled studies. The main tic reduction achieved in
those trials ranged between 25.8% and 39.0% [3–9]. In one
randomized, head-to-head trial, the goal was to compare
the efﬁcacy of aripiprazole and risperidone. The study was
carried out among 60 children and adolescents younger
than 18 and similar efﬁcacy was registered for both drugs
[10]. It can therefore be concluded, that aripiprazole is at
least as efﬁcient as other neuroleptics used in the treatment
of tics.
Interesting is comparison of aripiprazole and behavioral
therapy with regard to tic reduction. CBIT, comprehensive
behavioral intervention for tics, mostly based on HRT, when
compared to control therapy (psychoeducation and support
therapy), reduced tics by 4.1 after adjustment to placebo effect
(7.6 vs 3.5). 53% of children and adolescents and 38% of adults
reported much or very much tic reduction in (CGI) [11,12].
Although no clinical trials were conducted in order to compare
directly aripiprazole with behavioral therapy, the medication
seems to be slightly more beneﬁcial in tic reduction than
behavioral interventions based on CBIT/HRT.
4. Placebo effect
It is worth mentioning the sound placebo effect present in GTS.
In study by Sallee et al. placebo resulted in tic reduction of 7.1
according to TTS that corresponded to an average of 23.1%.
54.8% of patients experienced amelioration higher than 25%,
while 16.7% reached and upswing higher than 50% (TTS) and
38% of patients reported very pronounced or pronounced
positive outcome (CGI) [1]. In the study by Yoo et al. placebo
effect leaded to tic reduction by 9.6 (TTS) and in average 32.6%
in comparison to baseline rating, in 44.8% of patients
therapeutic effect was estimated to be good or very good
(CGI, score 1 or 2). Although partially those results could be
explained by natural waxing and waning nature of tics, the
signiﬁcance of placebo effect in GTS patients should be taken
into great consideration in the treatment of tics. Practical
implications are that results of open, uncontrolled studies
should always be interpreted critically, bearing in mind the
placebo effect.
Likewise, clinically signiﬁcant seems to be nocebo effect.
Adverse events of placebo were registered in 71.4% [2] and
40.9% of patients [1] in study conducted by Yoo et al. Total
number of adverse events was even higher in placebo group
than in those receiving aripiprazole (57 vs 56) [2].
5. The inﬂuence of aripiprazole on psychiatric
comorbidities
Sallee et al. detected positive impact of aripiprazole on
symptoms of ADHD, but only in the high-dose group. Better
results in SNAP-IV Scale (Swanson, Nolan and Pelham
Questionnaire-IV) were reached in terms of concentration,
hyperactivity and impulsivity. No signiﬁcant impact was
registered when it comes to OCD (Y-BOCS Scale, Yale-Brown
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 8 4 – 8 786Obsessive Compulsive Scale), depression (CDRS-R Scale,
Children's Depression Rating Scale Revised) and the level of
anxiety (PARS Scale, The Pediatric Anxiety Rating Scale). The
results of this randomized, double-blind, placebo-controlled
trial are contrary to the study conducted in Germany, that
showed signiﬁcant positive inﬂuence of aripiprazole on OCD
and tendency to improve depression, anxiety and ADHD
symptoms. However, this was an open, uncontrolled study,
that was carried out on a small group of patients (n = 44) and
only among adults [13]. In study by Yoo et al. no evaluation of
psychiatric comorbidities was conducted [2].
6. Side effects
Sallee et al. came to the conclusion, that use of high dose of
aripiprazole lead to 5.5 higher risk of adverse event that cause
drug dechallenge, while administration of low doses is not
related to such risk. In group of patients treated with
aripiprazole 12 patients were not able to ﬁnish the study (8
of them due to adverse events), the vast majority of which
were children with body mass <50 kg and receiving high dose
of the drug, 10 mg/day. In study by Yoo et al., none patient
dropped out of the study as the consequence of side effects.
The majority of patients experienced at least one side effect
(65.9% and 75.6% [1], and 75.0% [2]). The most common ones
were: sedation, sleepiness, tiredness and increased appetite
[1], moreover, nausea, headache, infections of upper respira-
tory tract, weight gain [2]. In contrast to other neuroleptics,
aripiprazole did not provoke hyperprolactinemia what is
probably related to partial agonistic impact of aripiprazole
on dopaminergic receptors [2]. The majority of adverse events
were mild or moderate, no severe side effect or death was
detected. Extrapyramidal complications were rare or clinically
insigniﬁcant [2] and were dose-dependent [1]. Sallee et al.
reported them in 13.3% of high-dose group and the most
frequent symptom was akathisia [1].
7. Dosing scheme
During the ﬁrst two days aripiprazole is administered in dose
2 mg/day, during the days 2–7 the dose is increased to 5 mg/
day and then, depending on clinical response, the dose could
be increased 5 mg/week [1,2]. It is estimated, that an average
effective dose is 5 mg for children with body mass <50 kg and
10 mg >50 kg. The maximal dose used in controlled trials was
20 mg/day [1,2]. In open studies, however, the dose up to
30 mg/day was used [13].
8. Summary
1. The efﬁcacy of aripiprazole in GTS was conﬁrmed in two
short-term, randomized, placebo-controlled, multicenter
clinical trial conducted among children and adolescents.
2. Aripiprazole reduces tics by 50% in average in approxi-
mately half of patients.
3. 2/3 of patients with GTS improve much or very much.4. The most frequent side effects are sedation, sleepiness,
tiredness and increased appetite.
9. Conclusions
1. Aripiprazole is an efﬁcient drug reducing tics in GTS among
children and adolescents.
2. Aripiprazole has level B recommendation and from 2014 is
registered by FDA in the treatment of GTS.
3. Aripiprazole is safe and well-tolerated drug in tic treatment.
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